samedan logo
 
 
 
spacer
home > ebr > summer 2019 > an answerable challenge
PUBLICATIONS
European Biopharmaceutical Review

An Answerable Challenge

While cancer and cardiovascular diseases continue to hold the top ranks of the causes of mortality in Europe and North America, we have become accustomed to the burden of disease from neurodegenerative conditions increasing, mostly as a consequence of population ageing. If one were to cast the net wider (not only focusing on conditions that have neurodegeneration as a cause, but all neurological disorders), one would see that these were the leading cause of disability-adjusted life years − which refer to the sum of lost life years and years lived with disability − worldwide in 2016. While infectious causes have decreased over the past 25 years, stroke and dementia continue to loom large across the globe (1). In high-income countries, these two conditions rank second and third respectively in terms of crude death rate.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
While cancer and cardiovascular diseases continue to hold the top ranks of the causes of mortality in Europe and North Dr Hermann Mucke is the owner and Chief Executive of H.M. Pharma Consultancy, a globally acting provider of consulting services to the pharmaceutical industry and academia, with headquarters in Vienna, Austria. After earning his Master’s and PhD degrees in biochemistry and molecular biology, he spent four years at the University of Vienna, Austria, before moving to industry, finally becoming an entrepreneur in 2000 when he set up his life sciences consultancy. An expert in drug repurposing, patenting, and knowledge management, Hermann has assisted companies of all sizes over the past 20 years.
spacer
Dr Hermann Mucke
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Thermo Fisher Scientific Adds Patterned Microchip-based Technology to Liquid Chromatography Portfolio

PHILADELPHIA – ASMS 2021 – (November 1, 2021) – Thermo Fisher Scientific, the world leader in serving science, today announced its acquisition of Belgium-based PharmaFluidics, the developer of the μPAC range of micro-chip-based chromatography column.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement